28 related articles for article (PubMed ID: 12408659)
1. The A581G Mutation in the Gene Encoding Plasmodium falciparum Dihydropteroate Synthetase Reduces the Effectiveness of Sulfadoxine-Pyrimethamine Preventive Therapy in Malawian Pregnant Women.
Gutman J; Kalilani L; Taylor S; Zhou Z; Wiegand RE; Thwai KL; Mwandama D; Khairallah C; Madanitsa M; Chaluluka E; Dzinjalamala F; Ali D; Mathanga DP; Skarbinski J; Shi YP; Meshnick S; ter Kuile FO
J Infect Dis; 2015 Jun; 211(12):1997-2005. PubMed ID: 25564249
[TBL] [Abstract][Full Text] [Related]
2. Drug-resistant malaria in Sudan: A review of evidence and scenarios for the future.
Adeel AA
Sudan J Paediatr; 2012; 12(1):8-20. PubMed ID: 27493325
[TBL] [Abstract][Full Text] [Related]
3. Frequencies distribution of dihydrofolate reductase and dihydropteroate synthetase mutant alleles associated with sulfadoxine-pyrimethamine resistance in Plasmodium falciparum population from Hadhramout Governorate, Yemen.
Bamaga OA; Mahdy MA; Lim YA
Malar J; 2015 Dec; 14():516. PubMed ID: 26693691
[TBL] [Abstract][Full Text] [Related]
4. Selection of pfdhfr/pfdhps alleles and declining artesunate/sulphadoxine-pyrimethamine efficacy against Plasmodium falciparum eight years after deployment in eastern Sudan.
Gadalla NB; Abdallah TM; Atwal S; Sutherland CJ; Adam I
Malar J; 2013 Jul; 12():255. PubMed ID: 23870667
[TBL] [Abstract][Full Text] [Related]
5. Molecular markers of anti-malarial drug resistance in Lahj Governorate, Yemen: baseline data and implications.
Mubjer RA; Adeel AA; Chance ML; Hassan AA
Malar J; 2011 Aug; 10():245. PubMed ID: 21854642
[TBL] [Abstract][Full Text] [Related]
6. Drug coverage in treatment of malaria and the consequences for resistance evolution--evidence from the use of sulphadoxine/pyrimethamine.
Malisa AL; Pearce RJ; Abdulla S; Mshinda H; Kachur PS; Bloland P; Roper C
Malar J; 2010 Jul; 9():190. PubMed ID: 20602754
[TBL] [Abstract][Full Text] [Related]
7. A systematic review and meta-analysis of evidence for correlation between molecular markers of parasite resistance and treatment outcome in falciparum malaria.
Picot S; Olliaro P; de Monbrison F; Bienvenu AL; Price RN; Ringwald P
Malar J; 2009 May; 8():89. PubMed ID: 19413906
[TBL] [Abstract][Full Text] [Related]
8. High frequency of Plasmodium falciparum CICNI/SGEAA and CVIET haplotypes without association with resistance to sulfadoxine/pyrimethamine and chloroquine combination in the Daraweesh area, in Sudan.
A-Elbasit IE; Khalil IF; Elbashir MI; Masuadi EM; Bygbjerg IC; Alifrangis M; Giha HA
Eur J Clin Microbiol Infect Dis; 2008 Aug; 27(8):725-32. PubMed ID: 18373107
[TBL] [Abstract][Full Text] [Related]
9. Plasmodium falciparum isolates in India exhibit a progressive increase in mutations associated with sulfadoxine-pyrimethamine resistance.
Ahmed A; Bararia D; Vinayak S; Yameen M; Biswas S; Dev V; Kumar A; Ansari MA; Sharma YD
Antimicrob Agents Chemother; 2004 Mar; 48(3):879-89. PubMed ID: 14982779
[TBL] [Abstract][Full Text] [Related]
10. Molecular surveillance of the antifolate-resistant mutation I164L in imported African isolates of Plasmodium falciparum in Europe: sentinel data from TropNetEurop.
Wichmann O; Jelinek T; Peyerl-Hoffmann G; Mühlberger N; Grobusch MP; Gascon J; Matteelli A; Hatz C; Laferl H; Schulze M; Burchard G; da Cunha S; Beran J; McWhinney P; Kollaritsch H; Kern P; Cuadros J; Alifrangis M; Gjørup I;
Malar J; 2003 Jun; 2():17. PubMed ID: 12869209
[TBL] [Abstract][Full Text] [Related]
11. Polymorphisms in Plasmodium falciparum dhfr and dhps genes and age related in vivo sulfadoxine-pyrimethamine resistance in malaria-infected patients from Nigeria.
Happi CT; Gbotosho GO; Folarin OA; Akinboye DO; Yusuf BO; Ebong OO; Sowunmi A; Kyle DE; Milhous W; Wirth DF; Oduola AM
Acta Trop; 2005 Sep; 95(3):183-93. PubMed ID: 16023986
[TBL] [Abstract][Full Text] [Related]
12. Geographical spread and structural basis of sulfadoxine-pyrimethamine drug-resistant malaria parasites.
Chaturvedi R; Chhibber-Goel J; Verma I; Gopinathan S; Parvez S; Sharma A
Int J Parasitol; 2021 Jun; 51(7):505-525. PubMed ID: 33775670
[TBL] [Abstract][Full Text] [Related]
13. Antifolates can have a role in the treatment of Plasmodium vivax.
Hawkins VN; Joshi H; Rungsihirunrat K; Na-Bangchang K; Sibley CH
Trends Parasitol; 2007 May; 23(5):213-22. PubMed ID: 17368986
[TBL] [Abstract][Full Text] [Related]
14. Pyrimethamine/sulfadoxine combination in the treatment of uncomplicated falciparum malaria: relation between dihydropteroate synthase/dihydrofolate reductase genotypes, sulfadoxine plasma levels, and treatment outcome.
Khalil I; Alifrangis M; Rønn AM; Gabar HA; Jelinek T; Satti GM; Bygbjerg IC
Am J Trop Med Hyg; 2002 Sep; 67(3):225-9. PubMed ID: 12408659
[TBL] [Abstract][Full Text] [Related]
15. High prevalence of quintuple mutant dhps/dhfr genes in Plasmodium falciparum infections seven years after introduction of sulfadoxine and pyrimethamine as first line treatment in Malawi.
Bwijo B; Kaneko A; Takechi M; Zungu IL; Moriyama Y; Lum JK; Tsukahara T; Mita T; Takahashi N; Bergqvist Y; Björkman A; Kobayakawa T
Acta Trop; 2003 Mar; 85(3):363-73. PubMed ID: 12659974
[TBL] [Abstract][Full Text] [Related]
16. Low-dose treatment with sulfadoxine-pyrimethamine combinations selects for drug-resistant Plasmodium falciparum strains.
Kun JF; Lehman LG; Lell B; Schmidt-Ott R; Kremsner PG
Antimicrob Agents Chemother; 1999 Sep; 43(9):2205-8. PubMed ID: 10471565
[TBL] [Abstract][Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
